Practical guidelines for the long-term treatment of psoriasis with efalizumab - 09/08/11
Doi : 10.1016/j.jaad.2005.12.017
Craig L. Leonardi, MD a, ⁎ 
, Kim A. Papp, MD, PhD b, Jan D. Bos, MD c
, Kim A. Papp, MD, PhD b, Jan D. Bos, MD c a From St. Louis University School of Medicine
b Probity Medical Research, Waterloo
c Academic Medical Center, University of Amsterdam
Reprint requests: Craig L. Leonardi, MD, Central Dermatology, 1034 S Brentwood Blvd, Ste 600, St. Louis, MO 63117.St. Louis, Missouri; Waterloo, Ontario, Canada; and Amsterdam, The Netherlands
| Supported by Genentech Inc and Serono International SA. Disclosures: Dr Leonardi has received educational grant support from and served on the speakers bureau and advisory board for Genentech Inc. Dr Papp is a consultant, an investigator, and an advisory board member for Genentech Inc, Serono International SA, and Xoma, LLC; he is on the Serono International SA speakers bureau. Dr Bos has no conflict of interest to disclose. |
© 2006
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 4S
P. S153 - avril 2006 Retour au numéro
Article précédent
- Table of contents
- Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial
- Alice B. Gottlieb, Tiffani Hamilton, Ivor Caro, Paul Kwon, Peter G. Compton, Craig L. Leonardi, for the Efalizumab Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?